Top

Published in:

01-08-2008 | Editorial

NICE continues to muddy the waters of osteoporosis

Authors: J. A. Kanis, J. E. Compston

Published in: Osteoporosis International | Issue 8/2008

Excerpt

The storm generated by the National Institute for Health and Clinical Excellence (NICE) over the appraisal of osteoporosis treatments in the UK continues unabated. An editorial in Bone earlier this year outlined the history of the prolonged appraisal process, begun in 2002, that continues to evaluate the cost-effectiveness of interventions for the primary and secondary prevention of osteoporotic fractures [1]. At that time NICE had issued its Final Appraisal Determinations (FADs) for primary and secondary prevention that restricted the use of interventions to generic alendronate [2, 3]. The appraisal was successfully appealed for this and other reasons. As a result, further consultation documents have been issued [4, 5]. The new documents now include appraisals for other treatments, including risedronate, raloxifene, strontium ranelate and (for secondary prevention only) teriparatide. Other changes have been microscopic despite public and private concern. What are these concerns, and why should they trouble the international readership of Osteoporosis International? …

Delmas PD, Siris ES (2008) NICE recommendations for the prevention of osteoporotic fractures in postmenopausal women. Bone 42:16–18PubMedCrossRef

National Institute for Health and Clinical Excellence (2007) Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. NICE, London (June)

National Institute for Health and Clinical Excellence (2007) Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. NICE, London (June)

National Institute for Health and Clinical Excellence (2008) Appraisal consultation document. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. NICE, London (March)

National Institute for Health and Clinical Excellence (2008) Appraisal consultation document. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. NICE, London (March)

House of Commons Health Committee, National Institute for Health and Clinical Excellence (2008) First Report of Session 2007–08, vol. 1. HC 27-I. The Stationery Office Limited, London. Available from http://www.publications.parliament.uk/pa/cm200708/cmselect/cmhealth/27/27.pdf. Accessed 20 April

Kanis JA, Adams J, Borgström F, Cooper C, Jönsson B, Preedy D, Selby P, Compston J (2008) Cost-effectiveness of alendronate. Bone 42:4–15PubMedCrossRef

Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M (2007) Corticosteroid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 11(7):1–256

Kanis JA, on behalf of the World Health Organization Scientific Group (2008) Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK

10.

Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397PubMedCrossRef

11.

Kanis JA, Adams J, Borgström F, Cooper C, Jönsson B, Preedy D, Selby P, Compston J (2008) Modelling cost-effectiveness for osteoporosis. Bone (in press)

12.

Stevenson M (2008) The population of health economic models is critical. Bone (in press)

13.

Zethraeus N, Borgstrom F, Strom O, Kanis JA, Jonsson B (2007) Cost-effectiveness of the treatment and prevention of osteoporosis—a review of the literature and a reference model. Osteoporos Int 18:9–23PubMedCrossRef

14.

Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733PubMedCrossRef

15.

Zethraeus N, Ström O, Borgström F, Kanis JA, Jönsson B (2008) The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden. Osteoporos Int (in press)

16.

Fujiwara S, Nakamura T, Orimo H, Hosoi T, Gorai I, Oden A, Johansson H, Kanis JA (2008) Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX™). Osteoporos Int 19:429–448PubMedCrossRef

17.

Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL, National Osteoporosis Foundation Guide Committee (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447PubMedCrossRef

18.

Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, Baim S, Favus MJ, Khosla S, Lindsay RL, National Osteoporosis Foundation Guide Committee (2008) Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 19:449–458PubMedCrossRef

19.

Leslie WD (2008) Manitoba Bone Density Program Committee. Absolute fracture risk reporting in clinical practice: a physician-centered survey. Osteoporos Int 19:459–463PubMedCrossRef

20.

Siminoski K, Leslie WD, Frame H, Hodsman A, Josse RG, Khan A, Lentle BC, Levesque J, Lyons DJ, Tarulli G, Brown JP (2007) Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment. J Clin Densitom 10:120–123PubMedCrossRef

21.

Nakamura T, World Health Organization (2007) Absolute risk for fracture and WHO guideline. Fracture risk assessments recommended by World Health Organization and Japanese guidelines for prevention and treatment of osteoporosis 2006. Clin Calcium 17:1022–1028PubMed

22.

Kurth AA, Pfeilschifter J (2007) Diagnosis and treatment of postmenopausal osteoporosis and osteoporosis in men. German Guidelines Update 2006. Orthopade 36:683–690PubMedCrossRef

23.

Czerwiński E, Badurski JE, Marcinowska-Suchowierska E, Osieleniec J (2007) Current understanding of osteoporosis according to the position of the World Health Organization (WHO) and International Osteoporosis Foundation. Ortop Traumatol Rehabil 9:337–356PubMed

24.

Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R, on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428PubMedCrossRef

25.

National Osteoporosis Guideline Group on behalf of the Bone Research Society, British Geriatrics Society, British Society of Rheumatology, Society of Endocrinology, British Orthopaedic Association, Primary Care Rheumatology Society, Osteoporosis 2000 and Osteoporosis Dorset (2008) Osteoporosis: clinical guideline for prevention and treatment. Circulated for consultation

26.

Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A and the National Osteoporosis Guideline Group (2008) Case finding for the management of osteoporosis with FRAX™—assessment and intervention thresholds for the UK. Osteoporos Int (in press)

Title: NICE continues to muddy the waters of osteoporosis
Authors: J. A. Kanis
J. E. Compston
Publication date: 01-08-2008
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 8/2008
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-008-0649-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

NICE continues to muddy the waters of osteoporosis

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2008

A C >T polymorphism located at position −1 of the Kozak sequence of CD40 gene is associated with low bone mass in Spanish postmenopausal women

Trend of hip fracture incidence in Germany 1995–2004: a population-based study

Natural history and risk factors for bone loss in postmenopausal Caucasian women: a 15-year follow-up population-based study

Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women

Osteoporosis treatment and fracture incidence: the ICARO longitudinal study

Clinical performance of osteoporosis risk assessment tools in women aged 67 years and older